Aquestive Therapeutics Q3 2023 EPS $(0.03) Beats $(0.11) Estimate, Sales $13.00M Beat $11.51M Estimate
Portfolio Pulse from vinayak@benzinga.com
Aquestive Therapeutics reported Q3 2023 earnings per share (EPS) of $(0.03), beating the analyst consensus estimate of $(0.11) by 72.73%. This is an 86.96% increase over the same period last year. The company also reported quarterly sales of $13.00 million, beating the analyst consensus estimate of $11.51 million by 12.96%, a 13.43% increase from last year.
November 06, 2023 | 10:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics reported better than expected Q3 2023 earnings and sales, which could positively impact the stock price.
Aquestive Therapeutics reported Q3 2023 earnings and sales that beat analyst estimates. This is generally seen as positive news for the company and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100